Skip to main content

Main menu

  • About Us
    • Leadership
    • Our Team
    • Vision, Mission and Values
    • Health and Economic Impact
    • Strategic Plan
  • Our Research
    • Research Focus
      • Brain Health
      • Cancer
      • Cardiovascular Conditions and Diseases
      • Digital Health
      • Health Policy
      • Immunity and Infectious Diseases
      • Joint Health and Mobility
      • Respiratory and Lung Health
      • Spinal Cord Injury and Rehabilitation
    • Research Centres and Programs
      • BC Centre on Substance Use
      • Centre for Cardiovascular Innovation
      • Centre for Clinical Epidemiology and Evaluation
      • Centre for Hip Health and Mobility
      • Centre for Lung Health
      • Djavad Mowafaghian Centre for Brain Health
      • Immunity and Infection Research Centre
      • International Collaboration On Repair Discoveries
      • Ovarian Cancer Research Centre
      • Vancouver Prostate Centre
      • Community Research Program
      • Emergency Medicine Research Program
      • Hematology Research Program
      • Rehabilitation Research Program
      • Skin Research Program
      • Other Research Focus Areas
    • News and Stories
    • Researcher Directory
    • Events and Workshops
  • Research Services
    • New to VCHRI
      • Working at VCHRI
      • Regulations and Training
      • Membership with VCHRI
    • Starting Your Project
      • Research Facilitation
      • Awards and Funding
      • Grant Management
      • Operational Approval
    • Developing Your Project
      • Clinical Trials Administration
      • Clinical Research Unit
      • CST Cerner at VCH
      • Research Privacy
      • Financial Policies and Procedures
    • Additional Support
      • Education and Training
      • Communications and Branding
      • Media Relations
      • Study Recruitment Support
      • Innovation and Industry Partnership
    • Internal Awards
    • Clinical Research
    • Innovation and Partnership
  • Participate in Research
    • Reasons to Participate
    • Participant Stories
    • Find a Study
    • Recruitment Support

User menu

  • Log in

Breadcrumb

  1. Home
  2. Our Research
  3. News and Stories
  4. Effective mild asthma management with lower steroid doses

Effective mild asthma management with lower steroid doses

Stories Oct 19, 2018 3 minutes

A combined treatment for patients with mild asthma reduces the need for steroid medication.

A groundbreaking study published in the New England Journal of Medicine could lead to a reduction in the amount of steroid medication patients need to take to manage their mild asthma. Lead investigator Dr. Mark FitzGerald, a researcher with Vancouver Coastal Health Research Institute (VCHRI), examined whether patients with mild asthma could benefit from a combination medication versus twice-daily inhaled steroids or non-steroid reliever inhalers on an as-needed basis. 

“Patients can have a tendency to overuse medication that relieves symptoms, but underuse medication that can prevent symptoms from occurring.”   

FitzGerald and colleagues’ double-blind study involved almost 4,000 patients 12 years of age or older with mild asthma. Asthma symptoms, such as difficulty breathing, are caused by inflammation or swelling in the airways.

Approximately 50 to 75 per cent of asthma patients have mild asthma, which can be managed effectively if medication is taken as prescribed.

Many asthma patients are prescribed inhaled corticosteroids, which help reduce inflammation and prevent asthma symptoms and exacerbations. However, many do not take this effective treatment and overuse the short-acting reliever inhaler they are prescribed for use when they experience difficulty breathing.

A possible new treatment to prevent asthma exacerbations 

During the one-year clinical trial, patients were separated into three groups and given different medications and treatment plans. One third of patients received a budesonide-formoterol inhaler to use on an as-needed basis, plus a twice-daily placebo. Another third received terbutaline—a short-acting reliever inhaler used to manage mild asthma symptoms—to use as needed, plus a twice-daily placebo. The final group received as-needed terbutaline, plus twice-daily budesonide maintenance therapy. 

Dr. Mark FitzGerald is the director of the Centre for Heart and Lung Health and a senior scientist at the Centre for Clinical Epidemiology and Evaluation. He is a member of the Respiratory Medicine Divisions at UBC and Vancouver General Hospital and co-director of the UBC Institute for Heart and Lung Health.

The results showed that the group that took budesonide-formoterol had better overall control of their asthma symptoms and a reduced risk of asthma exacerbation than those in the terbutaline only group. 

The budesonide-formoterol treatment was similar to the terbutaline plus twice-daily budesonide maintenance therapy in terms of its effectiveness at reducing the risk of asthma exacerbations. However, the budesonide-formoterol group did not need to take corticosteroids twice daily and inhaled only 17 per cent of the steroids that the terbutaline plus twice-daily maintenance group inhaled.

“With budesonide-formoterol, patients can manage their mild asthma and prevent exacerbations with much lower steroid doses than those who take regular inhaled corticosteroids.”  

Results of this trial could have huge implications for the 334 million people worldwide who suffer from asthma, but may be reluctant to take inhaled corticosteroids on a daily basis to manage their symptoms. It could also be a cost-effective measure, as it requires less medication overall.

“Reliever medications like terbutaline do not treat inflammation, which is the underlying cause of asthma symptoms,” notes FitzGerald. “Inhaled corticosteroids like budesonide do treat inflammation, which helps to prevent asthma exacerbations and can decrease the use of and reliance on reliever medications.” 

“Our research shows that symptom control and treatment efficacy can be achieved with an as-needed combined medication for patients with mild asthma.” 

An accompanying study co-investigated by Fitzgerald garnered similar findings. Both studies are scheduled to be submitted to regulatory agencies for approval and could soon result in a novel new approach to treating mild asthma.
 

Researchers

Mark FitzGerald

Related Articles

Giving voice to asthma and COPD patients

Research finds encouraging trends in B.C.’s approach to severe asthma

One in five new cases of childhood asthma in Canada are caused by traffic pollution

Share:

  • Facebook
  • Linkedin
  • Twitter
  • Email

Related Research Centres/Programs

Centre for Lung Health

Centre for Clinical Epidemiology and Evaluation

Get the latest research headlines in your inbox

Subscribe

Recent News and Stories

Type
Stories

Early intervention with cryoablation for better heart outcomes

Jan 22, 2023 cardiac, treatment options, stroke
Type
Stories

Keeping your head in the race: Cognitive impacts observed among ultra-marathon runners

Jan 20, 2023 cardiac, cognition, safety
Type
Stories

People in profile: Barbara Allan

Jan 17, 2023 people feature
See more news

Get updates!

Join our newsletter mailing list to stay up to date on features and releases.

Subscribe

Quick Links

  • News and Stories
  • Careers
  • Events
  • Media Enquiries

Follow Us

  • Twitter
  • LinkedIn

© 2023 VCHRI. All rights reserved.

  • Contact
  • Privacy Policy